Regeneron CSO Andrew J. Murphy sells shares under 10b5-1 plan
1 report, 1 independent
Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Andrew J. Murphy, Co-Chief Scientific Officer at Regeneron Pharmaceuticals, sold 4,147 shares on October 14, 2026, for approximately $3.20 million. These trades were executed under a Rule 10b5-1 trading plan. Separately, Murphy acquired 17,000 shares of common stock on October 13, 2026, through a non-qualified stock option.
From themarketsdaily.com
Why it matters
The transactions reflect activity by a key executive at Regeneron Pharmaceuticals. The sale of shares was part of a pre-established trading plan, which is a standard mechanism used by corporate insiders.
From themarketsdaily.com
Who's involved
- Andrew J. MurphyCo-Chief Scientific Officer at Regeneron Pharmaceuticals
- Regeneron PharmaceuticalsAmerican pharmaceutical company where Andrew J. Murphy serves